Coca-Cola is facing a lawsuit over claims that its Simply Orange Juice contains high levels of toxic chemicals known as PFAS, or “forever chemicals.”
According to the plaintiff, Joseph Lurenz, the beverage company deceived customers by marketing the juice as all-natural, despite third-party testing finding PFAS levels hundreds of times higher than federal limits for drinking water.
Exposure to high PFAS levels can increase the risk of various health problems, including cancer, fetal complications, liver disease, kidney or testicular cancer, and increased cholesterol levels.
The plaintiff, which claims the defendants knew the product contained PFAS but failed to disclose the information to consumers, is seeking monetary compensation, damages, and penalties for the company.
It is unknown how PFAS chemicals contaminated the water used to make the juice, and if the chemicals could also be in the packaging.


SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing
U.S. Reveals 2026 Medicare Star Ratings: Aetna, UnitedHealth Lead in Quality Scores
HSBC’s $13.6 Billion Take-Private Offer for Hang Seng Bank Gains Board Backing
Strategy Retains Nasdaq 100 Spot Amid Growing Scrutiny of Bitcoin Treasury Model
New Epstein Photos Surface Showing Trump as Lawmakers Near Document Release Deadline
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates
Robinhood Expands Sports Event Contracts With Player Performance Wagers
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
Singapore Growth Outlook Brightens for 2025 as Economists Flag AI and Geopolitical Risks
Oil Prices Slip in Asia as 2026 Supply Glut Fears and Russia-Ukraine Talks Weigh on Markets
Federal Judge Orders Restoration of SEVIS Status for Tufts PhD Student Rumeysa Ozturk
Asian Fund Managers Turn More Optimistic on Growth but Curb Equity Return Expectations: BofA Survey
Trump Signs Executive Order to Boost AI Research in Childhood Cancer
Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 



